The role involves leading clinical development strategies for Lunsekimig, a novel bi-specific nanobody targeting TSLP and IL-13 across multiple immunology disease areas.
Base: $206,250.00 - $343,750.00; Bonus/Equity: Not specified; Benefits: High-quality healthcare, wellness programs, 14 weeks gender-neutral parental leave
Must-have
Nice-to-have
Not specified